Live
Clinical OMICsA Spoonful of Hydrogel Keeps the Medicine in PlaceEndpoints NewsSciwind has two Western partners for its obesity drug, but is open to moreFierceBiotechNovartis' phase 1/2 win tees up regulatory talks about dystrophy drug from $12B Avidity takeoverLabiotechAdvancing corticosteroids and hormonal therapies for supply and scaleFierceBiotech‘Not simply saving cost’: Inside Astellas CEO’s 5-year strategy to counter Xtandi’s patent cliffLonza NewsSmall-Molecule CDMO Outlook: What Lies Ahead - DCAT Value Chain InsightsClinical OMICsPioneering Innovation in Transplant DiagnosticsFierceBiotechRoche nabs EU approval on label expansions for companion dx platformFierceBiotechGenentech executes another round of layoffs, with 3 VPs axedScienceLaser-boosted microscopes could reveal new drug targets, sharpen views inside cellsScienceThe ocean current that warms Europe may be more resilient than fearedClinical OMICsCyclana Bio Is Exploring the Extracellular Matrix to Treat Endometriosis
Endpoints News Mar 13, 2026

Roivant CEO, bullish on internal growth, dodges M&A chatter

Roivant CEO, bullish on internal growth, dodges M&A chatter

Original
Body unavailable. Use the original source.